Latest Breaking News On - Society for the immunotherapy of cancer - Page 1 : vimarsana.com

Breaking Ground in Prostate Cancer: BriaCell Announces Lead

Bria-Pros+ is based on BriaCell’s next generation personalized immunotherapy platformBria-Pros+ is capable of activating multiple types of immune cells,.

United statesUnited kingdomBritish columbiaJules abrahamWilliamv williamsSociety for the immunotherapy of cancerExchange commissionRegulation services providerToronto stock exchangeNeither the toronto stock exchangeCompany contactBriacell therapeutics corpCell therapeuticsGood manufacturing practiceInvestigational new drugActivates immune cells

Werewolf Therapeutics Appoints Michael Atkins, M D , to its Board of Directors

04.01.2024 - WATERTOWN, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) - Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of novel, conditionally activated INDUKINE therapeutics .

United statesWilliamm schollEllen lubmanMichael atkinsMelanoma research alliance medical advisory panelSociety for the immunotherapy of cancerVerge scientific communicationsProfessor at harvard medical schoolAdvisory councilCancer centerWerewolf therapeutics incCompany contactAcademy of immunooncologyWerewolf boardDeputy directorGeorgetown lombardi comprehensive cancer center

Mendus will participate in multiple investor and industry conferences in October and announces presentation of ALISON trial update at SITC

Mendus AB , a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced its participation in the following upcoming investor and industry conferences: LSX.

City ofUnited kingdomUnited statesSan diegoSan diego convention centerFrance generalCorey davisErik mantingMario brkuljLotta fermLeopold berteaLifesci advisorsSociety for the immunotherapy of cancerNordic congressValency communicationsCompany update

Pyxis Oncology Reports Financial Results for Second-Quarter 2023 and Provides Corporate Update

Third dose cohort initiated in Phase 1 trial of PYX-201, Pyxis Oncology s first ADC product candidate Preliminary data from two Phase 1 trials on track for late 2023 to early 2024 Apexigen. -August 11, 2023 at 07:01 am- MarketScreener

United statesSan diegoLaras sullivanCompany annual report on formSociety for the immunotherapy of cancerPyxis oncology incExchange commissionApexigen incPyxis oncologyChief executive officerAnnual meetingInternational associationLung cancerPrivate securities litigation reform actAnnual reportSecurities act

Pyxis Oncology Reports Financial Results for Second-Quarter 2023 and Provides Corporate Update

Pyxis Oncology Reports Financial Results for Second-Quarter 2023 and Provides Corporate Update
eagletribune.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eagletribune.com Daily Mail and Mail on Sunday newspapers.

San diegoUnited statesLaras sullivanCompany annual report on formSociety for the immunotherapy of cancerApexigen incPyxis oncology incExchange commissionPyxis oncologyChief executive officerAnnual meetingInternational associationLung cancerPrivate securities litigation reform actAnnual reportSecurities act